Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
53.67
+0.27 (0.51%)
May 13, 2025, 4:00 PM - Market closed
Exact Sciences Employees
Exact Sciences had 7,000 employees as of December 31, 2024. The number of employees increased by 400 or 6.06% compared to the previous year.
Employees
7,000
Change (1Y)
400
Growth (1Y)
6.06%
Revenue / Employee
$404,018
Profits / Employee
-$145,692
Market Cap
10.12B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7,000 | 400 | 6.06% |
Dec 31, 2023 | 6,600 | 200 | 3.13% |
Dec 31, 2022 | 6,400 | -100 | -1.54% |
Dec 31, 2021 | 6,500 | 1,500 | 30.00% |
Dec 31, 2020 | 5,000 | 890 | 21.65% |
Dec 31, 2019 | 4,110 | 2,133 | 107.89% |
Dec 31, 2018 | 1,977 | 709 | 55.91% |
Dec 31, 2017 | 1,268 | 532 | 72.28% |
Dec 31, 2016 | 736 | 59 | 8.71% |
Dec 31, 2015 | 677 | 441 | 186.86% |
Dec 31, 2014 | 236 | 134 | 131.37% |
Dec 31, 2013 | 102 | 15 | 17.24% |
Dec 31, 2012 | 87 | 26 | 42.62% |
Dec 31, 2011 | 61 | 26 | 74.29% |
Dec 31, 2010 | 35 | 16 | 84.21% |
Dec 31, 2009 | 19 | 15 | 375.00% |
Dec 31, 2008 | 4 | -10 | -71.43% |
Dec 31, 2007 | 14 | -8 | -36.36% |
Dec 31, 2006 | 22 | -27 | -55.10% |
Dec 31, 2005 | 49 | -22 | -30.99% |
Dec 31, 2004 | 71 | -11 | -13.41% |
Dec 31, 2003 | 82 | 7 | 9.33% |
Dec 31, 2002 | 75 | 7 | 10.29% |
Dec 31, 2001 | 68 | 24 | 54.55% |
Dec 31, 2000 | 44 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EXAS News
- 1 day ago - Exact Sciences Earns 2025 Great Place To Work® Certification™ - Business Wire
- 11 days ago - Exact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not Compelling - Seeking Alpha
- 11 days ago - Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance - Benzinga
- 12 days ago - Exact Sciences to Participate in May Investor Conference - Business Wire
- 12 days ago - Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Exact Sciences Announces First-Quarter 2025 Results - Business Wire
- 15 days ago - Exact Sciences to Highlight Cologuard® Test Adherence and Predicted Preference Data at Digestive Disease Week (DDW) 2025 - Business Wire
- 22 days ago - Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test - Business Wire